Philips and Digital China ratchet up lung cancer early screening in grassroots



China-based IT service provider Digital China Holdings Ltd, (HK.00861; TW.910861) and Dutch health tech giant Royal Philips (NYSE: PHG, AEX: PHIA) jointly launched SHINEFLY 2.0, a lung cancer screening teleradiology application and services platform. SHINEFLY 2.0 is an update to the SHINEFLY 1.0 product jointly introduced by the two sides in 2018. The product offers an overall solution based on SHINEFLY 1.0’s technology, including data acquisition, image reconstruction, image post-processing, results analysis, auxiliary diagnosis and other full-process services to support lung cancer early screening and diagnosis.

Jointly developed by Philips and Digital China, the system is designed to provide a solution to the growing imaging procedure volume in China, which exceeds the number of radiologists, and given the lack of qualified staff in primary and secondary hospitals. The technology supports doctors in carrying out diagnoses and precise follow-up in relation to nodules, improving the accuracy and efficiency of clinical diagnosis. SHINEFLY 2.0 includes CT equipment tailored for the primary care setting focused on lung cancer screening.

Reference:

Recent news
Argentina-based Laboratorios Bagó this week opened a new injectable drugs production facitlity in Buenos Aires.
Brazil’s health technology company WW8 last week launched its platform Athimos (www.athimos.com), a medical communications and patient records system.
Brazil’s Ministry of Health has requested the Oswaldo Cruz Foundation (Fiocruz) to supply the Unified Health System (SUS) with immunosuppressant tacrolimus for kidney and liver transplant patients.
Cuba’s state-run biopharmaceutical group BioCubaFarma this week presented its products to Chile’s biotechnology and pharmaceutical industry.
Beijing-headquartered Contract Research Organization (CRO) Joinn Laboratories (China) Co., Ltd (603127.SH) has entered into an equity purchase agreement with U.S.-based pre-clinical CRO Biomedical Research Models Inc​.
The National Health Commission released its annual statistical round-up of China’s national health system during 2018.
Shanghai-based Allist Pharmaceuticals Inc., raised RMB 1.18 billion (USD 162 million) via a Series A financing round led by Shenzhen Shiyu Investment Management Co., Ltd​.